Risdiplam for treating spinal muscular atrophy
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about risdiplam
Marketing authorisation indication
2.1 Risdiplam (Evrysdi, Roche) is indicated for 'the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics.
Price
2.3 The list price is £7,900 per 60mg/80ml vial. The company has a commercial arrangement, which would have applied if the technology had been recommended.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation